MEDIFAST INC (MED) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
MEDIFAST INC stock (MED) is currently trading at $9.61. MEDIFAST INC PS ratio (Price-to-Sales) is 0.28. Analyst consensus price target for MED is $12.00. WallStSmart rates MED as Sell.
- MED PE ratio analysis and historical PE chart
- MED PS ratio (Price-to-Sales) history and trend
- MED intrinsic value — DCF, Graham Number, EPV models
- MED stock price prediction 2025 2026 2027 2028 2029 2030
- MED fair value vs current price
- MED insider transactions and insider buying
- Is MED undervalued or overvalued?
- MEDIFAST INC financial analysis — revenue, earnings, cash flow
- MED Piotroski F-Score and Altman Z-Score
- MED analyst price target and Smart Rating
MEDIFAST INC
📊 No data available
Try selecting a different time range
Smart Analysis
MEDIFAST INC (MED) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
MEDIFAST INC (MED) Key Strengths (4)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
75.37% of shares held by major funds and institutions
Supporting Valuation Data
MEDIFAST INC (MED) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -36.90%, a shrinking business
Earnings declining -87.20%, profits shrinking
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
MEDIFAST INC (MED) Detailed Analysis Report
Overall Assessment
This company scores 45/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 4 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 0.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Price/Book. Valuation metrics including PEG Ratio (0.97), Price/Sales (0.28), Price/Book (0.55) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -36.90%, EPS Growth at -87.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -9.13%, Operating Margin at -10.40%, Profit Margin at -4.84%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -9.13% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -36.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MED Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MED's Price-to-Sales ratio of 0.28x trades at a deep discount to its historical average of 68.79x (1th percentile). The current valuation is 100% below its historical high of 1232.48x set in Dec 2010, and 6% above its historical low of 0.27x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for MEDIFAST INC (MED) · CONSUMER CYCLICAL › PERSONAL SERVICES
The Big Picture
MEDIFAST INC is in a turnaround phase, with management focused on restoring profitability. Revenue reached 386M with 37% decline year-over-year. The company is currently unprofitable, posting a -484.0% profit margin.
Key Findings
Revenue contracted 37% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -484.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor PERSONAL SERVICES industry trends, competitive moves, and regulatory changes that could impact MEDIFAST INC.
Bottom Line
MEDIFAST INC is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:28:21 AM
About MEDIFAST INC(MED)
NYSE
CONSUMER CYCLICAL
PERSONAL SERVICES
USA
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.